Clinical Trial

Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Study acronym: EVOKE-01
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The goal of this clinical study is to compare the study drug, sacituzumab govitecan-hziy (SG), versus docetaxel in participants with advanced or metastatic (cancer that has spread) non-small cell lung cancer (NSCLC).
Protocol Amendment History 29 amendments
This ClinicalTrials.gov record has been amended 29 times since 2021-10-11; most recent amendment 2026-04-22.
Status change: Recruiting → Active, Not Recruiting 2023-06-28
Status change: Not Yet Recruiting → Recruiting 2021-12-03
Trial Details
NCT Number NCT05089734
Lead Sponsor Gilead Sciences
Conditions Non-Small Cell Lung Cancer
Enrollment 603 participants
Start Date 2021-11-17
Primary Completion 2023-11-29 (estimated)
Study Completion 2027-01 (estimated)
Updated on ClinicalTrials.gov 2026-05-07